Search

everythinglearnresearchcommunity

for

Search:↓

Blocking certain proteins can reduce skin inflammation caused by cancer treatment.

Interleukin‐1 α reduces androgen receptor levels and increases certain cytokines in human scalp cells.

Inhibiting certain proteins harms hair follicle immunity and increases IL-33, affecting hair health.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

TNFα and interleukin-1 blockers reduce skin inflammation from EGFR antibody therapy.

Targeting IL-15 may help treat Alopecia Areata.

Testosterone increases cell growth and reduces IL-6 in gum cells.

Increased Toll-like receptors in blood cells may contribute to alopecia areata and could be a target for new treatments.

A substance called poly(I:C) increases a protein called carbonic anhydrase II in skin cells, which might help with skin defense and healing.

EGFRi/MEKi treatments cause hair follicles to lose some immune protection, leading to inflammation.

VR1 signaling can inhibit hair growth by affecting cell processes and increasing hair growth inhibitors.

cp-asiAR may effectively treat hair loss by targeting androgen receptors.

cp-asiAR may effectively treat androgenetic alopecia by promoting hair growth and reducing androgen receptor activity.

IL-17 plays a key role in severe hair loss in chronic alopecia areata.

Frontal fibrosing alopecia shows increased inflammation and JAK-STAT pathway activity without reduced hair proteins.

Scalp itching is common and hard to diagnose due to the complex nerve structure of the scalp.

Specific immune cells cause alopecia areata and blocking certain proteins can prevent it.

Recent findings suggest that genetic factors, immune system issues, and skin cell defects might contribute to the development of hidradenitis suppurativa.

Blocking EGFR can cause skin inflammation by disrupting IL-1 signaling.

Current and future treatments for alopecia areata focus on immunosuppression, immunomodulation, and protecting hair follicles.

New liposomal formulations may improve delivery of treatments to hair follicles, potentially helping with hair loss.

Dupilumab may cause hair loss in some patients with severe atopic dermatitis.

IL-1 alpha stops hair follicle growth and hair production.

Erlotinib causes skin inflammation through IL-1, which can be reduced by anakinra.

Dupilumab for skin problems might reactivate hair loss in some patients.

Dupilumab may help treat alopecia areata in children with atopic dermatitis, but it can also cause new hair loss.

New topical treatment using spherical nucleic acids shows promise in reducing psoriasis inflammation.

Dupilumab can improve both atopic dermatitis and alopecia universalis.

Activating TLR5 in the gut can extend lifespan and improve health in aged mice.

Opophytum forskahlii seed oil may help with anti-aging and hair growth.